div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: Rev DIABETES 61 Completa · Zinman B Wanner C Lachin JM et al Empagliflozin cardiovascular outcomes and mortality in type 2 diabetes N EnglJ Med 2015 373:2117—28 Neal src=https:reader034fdocumentsusreader034viewer20220423115ed8e3cf6714ca7f4768c296html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: Rev DIABETES 61 Completa · Zinman B Wanner C Lachin JM et al Empagliflozin cardiovascular outcomes and mortality in type 2 diabetes N EnglJ Med 2015 373:2117—28 Neal src=https:reader034fdocumentsusreader034viewer20220423115ed8e3cf6714ca7f4768c296html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: Rev DIABETES 61 Completa · Zinman B Wanner C Lachin JM et al Empagliflozin cardiovascular outcomes and mortality in type 2 diabetes N EnglJ Med 2015 373:2117—28 Neal src=https:reader034fdocumentsusreader034viewer20220423115ed8e3cf6714ca7f4768c296html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 4button div class=trans-image amp-img class=trans-thumb alt=Page 4: Rev DIABETES 61 Completa · Zinman B Wanner C Lachin JM et al Empagliflozin cardiovascular outcomes and mortality in type 2 diabetes N EnglJ Med 2015 373:2117—28 Neal src=https:reader034fdocumentsusreader034viewer20220423115ed8e3cf6714ca7f4768c296html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 5button div class=trans-image amp-img class=trans-thumb alt=Page 5: Rev DIABETES 61 Completa · Zinman B Wanner C Lachin JM et al Empagliflozin cardiovascular outcomes and mortality in type 2 diabetes N EnglJ Med 2015 373:2117—28 Neal...